Oppenheimer Asset Management Inc. Has $3.11 Million Stake in Natera, Inc. (NASDAQ:NTRA)

Oppenheimer Asset Management Inc. boosted its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 21.1% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 24,464 shares of the medical research company's stock after buying an additional 4,267 shares during the period. Oppenheimer Asset Management Inc.'s holdings in Natera were worth $3,106,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the stock. Itau Unibanco Holding S.A. bought a new stake in shares of Natera in the second quarter valued at about $28,000. Quarry LP boosted its holdings in Natera by 148.4% in the 2nd quarter. Quarry LP now owns 318 shares of the medical research company's stock valued at $34,000 after purchasing an additional 190 shares during the period. GAMMA Investing LLC grew its position in shares of Natera by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company's stock worth $35,000 after purchasing an additional 108 shares in the last quarter. Covestor Ltd raised its position in shares of Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company's stock valued at $47,000 after buying an additional 95 shares in the last quarter. Finally, Tobam bought a new stake in shares of Natera in the second quarter valued at approximately $74,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Stephens reaffirmed an "overweight" rating and issued a $125.00 price objective on shares of Natera in a report on Friday, August 9th. TD Cowen boosted their price target on Natera from $155.00 to $175.00 and gave the company a "buy" rating in a research note on Wednesday. StockNews.com cut shares of Natera from a "hold" rating to a "sell" rating in a research report on Thursday. Canaccord Genuity Group raised their target price on shares of Natera from $150.00 to $165.00 and gave the company a "buy" rating in a report on Wednesday. Finally, Sanford C. Bernstein upped their price target on shares of Natera from $125.00 to $135.00 and gave the stock an "outperform" rating in a report on Wednesday, October 30th. One analyst has rated the stock with a sell rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $137.65.

Natera Trading Down 3.3 %

NASDAQ:NTRA traded down $5.05 during mid-day trading on Friday, hitting $146.06. 2,242,843 shares of the company's stock were exchanged, compared to its average volume of 1,338,689. Natera, Inc. has a fifty-two week low of $52.01 and a fifty-two week high of $167.79. The company has a current ratio of 4.39, a quick ratio of 4.01 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $19.28 billion, a P/E ratio of -82.99 and a beta of 1.53. The company has a 50 day simple moving average of $127.38 and a 200-day simple moving average of $115.61.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.31. The company had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Natera's revenue was up 63.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.95) earnings per share. As a group, research analysts expect that Natera, Inc. will post -1.96 earnings per share for the current year.

Insider Buying and Selling at Natera

In other news, CEO Steven Leonard Chapman sold 5,024 shares of the business's stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $128.48, for a total value of $645,483.52. Following the transaction, the chief executive officer now owns 195,686 shares in the company, valued at approximately $25,141,737.28. The trade was a 2.50 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gail Boxer Marcus sold 2,212 shares of the stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $158.53, for a total transaction of $350,668.36. Following the sale, the director now owns 19,386 shares of the company's stock, valued at approximately $3,073,262.58. This trade represents a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 36,821 shares of company stock worth $4,776,878. Insiders own 7.60% of the company's stock.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.